The Semaglutide Packaging Opportunity Cdmo Plays Onesource Shaily Engineering In Focus

Shaily Cdmo For Global Pharma And Platform Devices Shaily engineering: 75% of the first filers for semaglutide in canada have tie ups with co, setting up new manufacturing facility in abu dhabi for `150 cr. Shares of onesource specialty pharma and shaily engineering plastics saw heightened investor interest in friday’s trade, driven by renewed optimism around the fast growing global glp 1 drug ecosystem, particularly semaglutide based therapies and india’s emerging role in the supply chain for injectable drugs and delivery devices.

Shaily Cdmo For Global Pharma And Platform Devices This piece is part of my ongoing glp‑1 and cdmo mini series in invest in india – guide, where i track how global pharma reshoring is creating long duration equity opportunities in india’s manufacturing and healthcare complex. India based onesource specialty pharma has laid out an ambitious growth strategy aimed at achieving $400 million in revenue by fy28, fuelled by booming global demand for weight loss drugs such as semaglutide and a thriving contract development and manufacturing organisation (cdmo) business. Onesource specialty pharma is gearing up to support the global launch of a generic anti diabetes and obesity medication in early 2026, which, chief executive officer neeraj sharma says, will be a. Shaily engineering plastics limited has delivered an exceptionally strong q1 fy26, propelled by its booming healthcare segment and strategic investments in glp 1 pen manufacturing.

Shaily Cdmo For Global Pharma And Platform Devices Onesource specialty pharma is gearing up to support the global launch of a generic anti diabetes and obesity medication in early 2026, which, chief executive officer neeraj sharma says, will be a. Shaily engineering plastics limited has delivered an exceptionally strong q1 fy26, propelled by its booming healthcare segment and strategic investments in glp 1 pen manufacturing. While the delay may impact short term demand visibility for shaily, analysts remain optimistic about the long term growth prospects of semaglutide linked supplies amid booming global demand for glp 1 based therapies. Mumbai: with sales of weight loss drugs surging and set to go up even more as semaglutide goes off patent early next year, a low profile manufacturer of injector pens, gujarat based shaily engineering plastics, is set to reap a windfall. its stock has nearly doubled over the past 12 months. Indian contract drug manufacturer onesource specialty pharma is positioning itself for significant growth as the patent for semaglutide, the active ingredient in blockbuster weight loss drugs, approaches expiration in early 2026. With over 20 clients in the glp 1 class of medicines to treat weight loss and diabetes, onesource specialty pharma expects to be part of the first wave of generics making semaglutide in canada.

Shaily Cdmo For Global Pharma And Platform Devices While the delay may impact short term demand visibility for shaily, analysts remain optimistic about the long term growth prospects of semaglutide linked supplies amid booming global demand for glp 1 based therapies. Mumbai: with sales of weight loss drugs surging and set to go up even more as semaglutide goes off patent early next year, a low profile manufacturer of injector pens, gujarat based shaily engineering plastics, is set to reap a windfall. its stock has nearly doubled over the past 12 months. Indian contract drug manufacturer onesource specialty pharma is positioning itself for significant growth as the patent for semaglutide, the active ingredient in blockbuster weight loss drugs, approaches expiration in early 2026. With over 20 clients in the glp 1 class of medicines to treat weight loss and diabetes, onesource specialty pharma expects to be part of the first wave of generics making semaglutide in canada.